KRAS and lung cancer: Most of the cancer signaling pathways mutated in lung cancer, like RAS-RAF-MEK-MAPK pathway, are mutated in 58% of all NSCLC tumor’s and 76% of lung adenocarcinomas [83], and KRAS and EGFR pathways, KEAP1/NRF2 pathway, etc., have a great impact on major metabolic pathways like glucose metabolism, amino acid metabolism pathways, and reactive oxygen species (ROS) regulation [84].